Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

PD-L1/TGFβ联合阻断可促进免疫排斥肿瘤中干细胞样CD8 T细胞的扩增和分化。

阅读:25
作者:Alessandra Castiglioni #,Yagai Yang #,Katherine Williams #,Alvin Gogineni,Ryan S Lane,Amber W Wang,Justin A Shyer,Zhe Zhang,Stephanie Mittman,Alan Gutierrez,Jillian L Astarita,Minh Thai,Jeffrey Hung,Yeqing Angela Yang,Tony Pourmohamad,Patricia Himmels,Marco De Simone,Justin Elstrott,Aude-Hélène Capietto,Rafael Cubas,Zora Modrusan,Wendy Sandoval,James Ziai,Stephen E Gould,Wenxian Fu,Yulei Wang,James T Koerber,Shomyseh Sanjabi,Ira Mellman,Shannon J Turley,Sören Müller

Abstract

TGFβ signaling is associated with non-response to immune checkpoint blockade in patients with advanced cancers, particularly in the immune-excluded phenotype. While previous work demonstrates that converting tumors from excluded to inflamed phenotypes requires attenuation of PD-L1 and TGFβ signaling, the underlying cellular mechanisms remain unclear. Here, we show that TGFβ and PD-L1 restrain intratumoral stem cell-like CD8 T cell (TSCL) expansion and replacement of progenitor-exhausted and dysfunctional CD8 T cells with non-exhausted T effector cells in the EMT6 tumor model in female mice. Upon combined TGFβ/PD-L1 blockade IFNγhi CD8 T effector cells show enhanced motility and accumulate in the tumor. Ensuing IFNγ signaling transforms myeloid, stromal, and tumor niches to yield an immune-supportive ecosystem. Blocking IFNγ abolishes the anti-PD-L1/anti-TGFβ therapy efficacy. Our data suggest that TGFβ works with PD-L1 to prevent TSCL expansion and replacement of exhausted CD8 T cells, thereby maintaining the T cell compartment in a dysfunctional state.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。